SNGX Stock Alert Soligenix, Inc.

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
Soligenix, Inc. SNGX Company Overview 

Stock Message Board http://investorshangout.com/search?q=SNGX&...mp;yt1=Go!

Soligenix, Inc. SNGX Current Price and Quotes
Last Price 2.19
Previous Close 2.09 Open 2.06
Daily Range 2.20 - 2.06 52wk Range 2.48 - 0.38
Volume 49,236 Dividend N/A
Average Vol (3m) 103,312 Yield N/A
Soligenix, Inc. SNGX
Company Information

29 Emmons Drive
Suite C-10
Princeton, NJ 08540

Website: http://www.soligenix.com
Phone: 609-538-8200

Soligenix, Inc. SNGX
Soligenix, Inc. is a development stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as oral mucositis, pediatric Crohn's disease, acute radiation enteritis, and Graft-versus-Host dis...



Soligenix, Inc. SNGX
Financial Reportings and Disclosures

Reporting Status U.S. Reporting: SEC Filer
Audited Financials Audited
Latest Report Jun 30, 2013 10-Q
CIK 0000812796
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data

SIC - Industry Classification 2834 - Pharmaceutical preparations
Business Status Development Stage Company a/o Jun 10, 2013
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts

Christopher J. Schaber President, CEO
Joseph M. Warusz Vice President, Acting CFO, Principal Acct. Officer
Company Directors

Keith Brownlie
Gregg Lapointe
Robert Rubin
Jerome Zeldis
Company Notes

Formerly=DOR BioPharma, Inc. until 9-2009
Formerly=Endorex Corp. until 12-01
Formerly=ImmunoTherapeutics, Inc. until 9-96
Service Providers

Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available

Soligenix, Inc. SNGX
SNGX Security Details

Share Structure

Market Value1 $39,773,718 a/o Sep 30, 2013
Shares Outstanding 19,030,487 a/o Aug 07, 2013
Float Not Available
Authorized Shares 50,000,000 a/o Jun 07, 2013
Par Value  0.001
Shareholders

Shareholders of Record 940 a/o Feb 26, 2013
Security Notes

New Issue=6-87 500,000 shs in units (1 sh Com & 1 Class A Warr 7-31-92) at $4 per unit by Seaboard Planning Corp.
Note=4-18-06 deleted from AMEX
Capital Change=shs decreased by 1 for 15 split Pay date=06/11/1997.
Capital Change=shs decreased by 1 for 20 split. Pay date=02/01/2012.
Short Selling Data

Short Interest 345,837 (14.89%)
Sep 13, 2013
Significant Failures to Deliver  No
Transfer Agent(s)

American Stock Transfer & Trust Company

Soligenix, Inc. SNGX Recent News

Sept 25, 2013 Soligenix Awarded NIAID Contract Valued up to $6.4 Million for the Development of OrbeShield(TM) in GI ARS
Sept 19, 2013 Soligenix Awarded BARDA Contract Valued up to $26.3 Million for Advanced Development of OrbeShield(TM) in GI ARS
Sept 16, 2013 FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
Sept 9, 2013 OTC Signal Daily Stock Watch - Soligenix (OTCBB: SNGX)
Sept 5, 2013 Soligenix to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
Aug 12, 2013 Soligenix Reports Second Quarter 2013 Financial Results, and Highlights Recent Accomplishments
Jul 8, 2013 Soligenix Announces Commercial Collaboration with SciClone Pharmaceuticals in China for SGX942 in the Treatment of Oral Mucositis


Soligenix, Inc. SNGX Financials
Period Ending Dec 31, 2012 Dec 31, 2011 Dec 31, 2010 Dec 31, 2009
Total Revenue 3,145 7,663 1,948 2,816
Cost of Revenue 2,593 2,108 1,638 1,484
Gross Profit 552 5,555 309 1,332
Operating Expenses

Research and Development 2,609 6,273 5,986 4,523
Sales, General and Admin. 2,633 2,242 2,201 2,860
Non-Recurring Items - - - -
Other - - - -
Operating Income (4,691) (2,960) (7,878) (6,051)
Income From Continuing Operations

Add'l Income/Expense Items 6 7 247 20
Earnings Before Interest and Tax (4,684) (2,953) (7,632) (6,032)
Interest Expense - - 1 3
Earnings Before Tax (4,684) (2,953) (7,632) (6,034)
Income Tax (521) (574) (246) -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (4,163) (2,379) (7,387) (6,034)
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (4,163) (2,379) (7,387) (6,034)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (4,163) (2,379) (7,387) (6,034)

SNGX Soligenix, Inc. Research DD Guide

Stock Message Board http://investorshangout.com/search?q=SNGX&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/SNGX/quote
Stock Chart http://www.otcmarkets.com/stock/SNGX/chart
Company Info http://www.otcmarkets.com/stock/SNGX/company-info
Recent News http://www.otcmarkets.com/stock/SNGX/news
Financials http://www.otcmarkets.com/stock/SNGX/financials
Filings and Disclosure http://www.otcmarkets.com/stock/SNGX/filings
Short Sales http://www.otcmarkets.com/stock/SNGX/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/SNGX/insider-transactions
Research Reports http://www.otcmarkets.com/stock/SNGX/research
Summary http://finance.yahoo.com/q?s=SNGX
Historical Prices http://finance.yahoo.com/q/hp?s=SNGX+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=SNGX
Basic Chart http://finance.yahoo.com/q/bc?s=SNGX+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=SNGX+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=SNGX+Headlines
Press Releases http://finance.yahoo.com/q/p?s=SNGX+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=SNGX+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=SNGX+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=SNGX+Industry
Major Holders http://finance.yahoo.com/q/mh?s=SNGX+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=SNGX+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=SNGX+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=SNGX
Balance Sheet http://finance.yahoo.com/q/bs?s=SNGX
Cash Flow http://finance.yahoo.com/q/cf?s=SNGX+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/SNGX
Market Watch http://www.marketwatch.com/investing/stock/SNGX
Bloomberg http://www.bloomberg.com/quote/SNGX:US
Morningstar http://quotes.morningstar.com/stock/s?t=SNGX
Bussinessweek http://investing.businessweek.com/research/st...icker=SNGX
Barchart http://www.barchart.com/quotes/stocks/SNGX
OTC Short Report http://otcshortreport.com/index.php?index=SNGX
Investopedia http://www.investopedia.com/markets/stocks/SNGX/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Diving Deep into the Whales' Activity with IBM Stock

Updated Category News Views 162

Understanding Recent Moves in IBM's Options Trading Recently, major financial players have made notable bullish moves concerning IBM. As we analyze the options trading history for International Business Machines, or IBM (NYSE: IBM), we uncover 12 unusual trades reflecting traders' sentiments. Trader Sentiment Breakdown Upon examining the trades, we find that 41% of the...

Continue Reading
Vestis Corporation Faces Important Lawsuit Deadline Ahead

Updated Category News Views 136

Critical Update on Vestis Corporation's Shareholder Lawsuit In a crucial development, the law firm Levi & Korsinsky has alerted investors regarding an impending deadline to participate in a class action lawsuit related to Vestis Corporation (NYSE: VSTS). This lawsuit aims to secure recoveries for investors who may have lost money due to alleged securities fraud. The lead...

Continue Reading
Equinor ASA Engages in Significant Share Buy-Back Activity

Updated Category News Views 90

Equinor ASA's Share Buy-Back Initiative Equinor ASA has recently made headlines with its latest share buy-back program, specifically the fourth tranche designated for the upcoming 2025 fiscal year. This strategic move aligns with the company's commitment to enhancing shareholder value and represents a proactive approach in managing its capital. Overview of the Buy-Back...

Continue Reading
Savoring the Flavor: QDOBA's National Burrito Day Celebration

Updated Category News Views 425

Celebrating National Burrito Day with QDOBA's Special Promotion QDOBA, a leading fast-casual Mexican restaurant, is kicking off National Burrito Day with an irresistible buy one, get one free offer, also known as "burrito insurance." This unique promotion is designed for the die-hard burrito lovers who believe that two burritos are better than one. In a fun twist, this...

Continue Reading
UK Competition Watchdog Challenges Google's Advertising Strategies

Updated Category News Views 109

UK Competition Watchdog Takes Action Against Google Recently, the UK's competition watchdog released significant findings about Google's practices in the advertising industry. The regulator has provisionally determined that Google (NASDAQ: GOOGL) has misused its dominant market position by managing both its publisher ad server and purchasing tools in a manner that...

Continue Reading